Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
Clinical trial NCT03411031 · TERMINATED
Trial details
- NCT number
- NCT03411031
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-04
- Primary completion
- 2021-02-18
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.